- Phare
- Validé par KD/KO
Anticorps Recombinant de lapin anti-NRF2, NFE2L2
NRF2, NFE2L2 Recombinant Antibody for WB, IHC, IF/ICC, FC (Intra), IP, Indirect ELISA, ChIP-qPCR
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain
Applications
WB, IHC, IF/ICC, FC (Intra), IP, Indirect ELISA, ChIP-qPCR
Conjugaison
Non conjugué
CloneNo.
1I21
N° de cat : 80593-1-PBS
Synonymes
Galerie de données de validation
Informations sur le produit
80593-1-PBS cible NRF2, NFE2L2 dans les applications de WB, IHC, IF/ICC, FC (Intra), IP, Indirect ELISA, ChIP-qPCR et montre une réactivité avec des échantillons Humain
Réactivité | Humain |
Hôte / Isotype | Lapin / IgG |
Clonalité | Recombinant |
Type | Anticorps |
Immunogène | NRF2, NFE2L2 Protéine recombinante Ag9489 |
Nom complet | nuclear factor (erythroid-derived 2)-like 2 |
Masse moléculaire calculée | 605 aa, 68 kDa |
Poids moléculaire observé | 110 kDa, 68 kDa |
Numéro d’acquisition GenBank | BC011558 |
Symbole du gène | NRF2 |
Identification du gène (NCBI) | 4780 |
Conjugaison | Non conjugué |
Forme | Liquide |
Méthode de purification | Purification par protéine A |
Tampon de stockage | PBS only |
Conditions de stockage | Store at -80°C. 20ul contiennent 0,1% de BSA. |
Informations générales
NRF2, also named as NFE2L2, belongs to the bZIP family and CNC subfamily. It is a transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes. NRF2 is important for the coordinated up-regulation of genes in response to oxidative stress. It may be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. Nrf2 is a key player in the regulation of genes encoding for many antioxidative response enzymes.The expression of NRF2 may be induced under oxidative stress (PMID:14567983).In lung cancer, Nrf2 activation in malignant cells has been associated with tumor progression and chemotherapy resistance(PMID:20534738). Identifying patients with abnormal NRF2 expression may be important for selection for chemotherapy in NSCLC. As new investigators break into the emerging field of Nrf2 research, confusion regarding the correct migratory pattern of Nrf2 is causing doubts about the accuracy and reproducibility of published results. This letter provides solid evidence that the actually observed molecular weight of Nrf2 is about 70kDa and 95-110 kDa. (PMID: 22703241).